Breast Cancer Subtypes

Emily BurkeBiotech Basics, Cancer, Genetics, Mechanism of Action

FOUR MOLECULAR VARIANTS EXPLAINED Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating — even for the most resilient person. Simply put, breast cancer is a complex disease. A diagnosis can be derived from any combination of the factors listed above — or, none at all. The National Cancer Institute (Bethesda, MD) has outlined four molecular subtypes of the disease. … Read More

Cell Signaling Explained

Emily BurkeBiotech Basics, Cancer, Deoxyribonucleic Acid (DNA), The WEEKLY

UNDERSTANDING THE DISEASE PROCESS Greetings from BIO 2017! It’s been a busy week here at the BIO International Convention here in San Diego, CA. At our convention booth, this year’s giveaway was our book written especially for non-scientists: The Biotech Primer: An insider’s guide to the biotech and pharma industry. If you weren’t at the convention to stop by and … Read More

The Biotech Primer BIO 2017 Preview

Emily BurkeBiotech Basics, Business of Biotech, The WEEKLY

Biotech Primer At BIO 2017 Biotech Primer will be headlining a few events at the BIO 2017 Annual International Convention in San Diego, CA next week. Will you be there? If so, please join us! Learn the fundamentals of biotechnology in our all-day class BioBriefing: Biotech for the Non-Scientist on Monday, June 19th. SOLD OUT What are the most popular topics in the WEEKLY? Attend Readers’ … Read More

A Skin Cell With Stem Cell Diversity?

Emily BurkeBiologics, Clinical Trials, Drug Development, Drug Targets, Term of the Week, The WEEKLY

INDUCED PLURIPOTENT STEM CELLS SHOW PROMISE Imagine being able to reprogram one of your own skin cells to produce a functioning nerve cell or section of cardiac tissue. This may sound like science fiction — but the groundwork for this to become a reality is already in the works as researchers expand their ability to create and manipulate induced pluripotent stem … Read More

Epigenome: Writing, Reading & Erasing

Emily BurkeCancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genomics, Mechanism of Action, Small Molecule Drugs

FOUNDATIONS OF EPIGENETICS Genetic mutations — changes in the order of the A, C, G, and T nucleotide bases that make up a gene — have been the primary focus of cancer researchers over the last several decades. By sussing out mutations involved in regulating cell growth and division, scientists better understand the molecular range of different cancers and consequently develop … Read More